�嶡��-ˮ���ܼ���ϵ���ɷ��Ʊ�������ɼ��֬����

??OBJECTIVE To prepare docetaxel liposomes by freeze-drying of tert-butyl alcohol (TBA)/water cosolvent system and evaluate the in vitro and in vivo properties. METHODS The formulation was optimized by single factor screening experiments. The effects of TBA/water ratio, lipid/drug ratio, sucrose/lipid ratio and mixing temperature on encapsulation efficiency were investigated. The in vitro release profiles were also investigated with docetaxel injection(Duopafei^?k) as control. RESULTS The formulated liposomes had a mean size of 263 nm with entrapment efficiency of (88.45??1.63)% at TBA/water ratio 50??50, lipid/ drug ratio 10??1, sucrose/lipid ratio 5??1 and mixing temperature 60 ??. In vitro drug release from liposomes lasted for 48 h. CONCLUSION Freeze-drying of TBA/water cosolvent system method may be feasible to prepare docetaxel liposomes.     

�Ļ��ؽ鵼�Ĺǰ���޽��ｺ�����Ʊ�����������

??OBJECTIVE To prepare atorvastatin-loaded tetracycline-PEG-PLGA(TC-PEG-PLGA/ATO) polymeric micelles, and investigate its pharmaceutical characteristics and targeting function in vitro. METHODS The amphiphilic TC-PEG-PLGA conjugate was synthesized via an esterification reaction and identified by the ¹H-NMR. Water insoluble atorvastatin was loaded on TC-PEG-PLGA conjugate micelles via dialysis method. The morphology of TC-PEG-PLGA/ATO micelles was observed under transmission electron microscope. The particle size distribution and Zeta potential of TC-PEG-PLGA/ATO micelles were determined by dynamic light scattering method. The drug loading and encapsulation efficiency were measured by HPLC, and in vitro release behavior was investigated via dialysis method. In vitro cytotoxicity was assessed via MTT assay, and bone-targeting activity was investigated via binding to the hydroxyapatite powder. RESULTS TC-PEG-PLGA/ATO micelle was prepared successfully, and its particle size and Zeta potential were (47.2??4.7) nm and (-14.25??0.31) mV. The encapsulation efficiency and drug loading rate were(98.2??1.51)% and (8.71??0.23)%, respectively. Moreover, the accumulative release of ATO in vitro was about 70% in 48 h, which indicated that the drug was released slowly from the micelles. In vitro cell evaluation showed that TC-PEG-PLGA conjugate micelles were great biocompatibility with MC3T3-E1 cells within the concentration range of 100-500 ??g??mL^-1. In vitro targeting performance indicated that the proportion of the TC-PLGA NPs bound to Hap(87.94%) was greater than the bound proportion of PLGA NPs(18.59%). CONCLUSION The TC-PEG-PLGA/ATO micelles exhibit small partical size and good stability, and significantly increased ATO content in aqueous solution. TC-PEG-PLGA/ATO micelles have good delayed release behavior, safety and binding efficacy to the hydroxyapatite powder.     

�д���������������������ԭλ�������о�

??OBJECTIVE To prepare ion-sensitive ophthalmic in situ gel containing bendazac lysine (BDZL-ISG) and preliminarily study its rheological behavior, in vitro drug release, corneal permeation, and pharmacokinetics in rabbit aqueous humor. METHODS Single factor investigation was carried out to optimize the formulation, taking viscosity and gelling capacity as evaluation indices. Using aqueous solution or eye drops as control, the in vitro release of the formulation was evaluated by dialysis membrane method. Then, the corneal permeation experiment of the optimum formulation was carried out with Franz diffusion cell. The pharmacokinetics of BDZL-ISG in rabbit aqueous humor was preliminarily studied by microdialysis. RESULTS Compared with the control group, the optimum formulation had shear thinning behavior and significant sustained release effect. There was no significant difference in the corneal permeation between the two groups. The RESULTS of pharmacokinetic study showed that ??_max (13.25 ??g??L^-1) and AUC_0-t of BZDL-ISG were 2.38 and 2.2 times higher than those of BDZL eye drops respectively, which suggested that the ocular bioavailability of BDZL was greatly enhanced by the optimum in situ gel formulation. CONCLUSION With significant sustained release effect, the ion-sensitive ophthalmic in situ gel will become a promising alterative formulation for bendazac lysine for treatment of cataracts.     

��ŵ����-���Դ���̼��������ɢ��˫����͸�ÿ���Ƭ���о�

??OBJECTIVE To improve the dissolution rate of fenofibrate (FNB) by using starch source mesoporous carbon (SMC) as a carrier and achieve controlled release of the drug by utilizing double-layer osmotic pump technology to improve the oral bioavailability. METHODS FNB was loaded into the mesoporous of NMS by adsorption method to prepare the drug loading system (FNB-SMC). Differential scanning calorimetry (DSC) and powder X-ray diffraction (PXDR) were used to characterize the present state of the drug before and after being loaded. The dissolution rate of FNB-SMC was investigated by in vitro dissolution test, and the formulation of the double-layer osmotic pump tablets of FNB-SMC was optimized. The oral bioavailability of the self-made tablet was investigated by in vivo experiment in rabbits. RESULTS FNB existed in the mesoporous of SMC in an amorphous state. The in vitro dissolution test showed that NMS could significantly increase the dissolution rate of FNB, and the double-layer osmotic pump technology could achieve Zero-order release of the drug. The in vivo experiments showed that the oral bioavailability of the self-made tablets was significantly improved. CONCLUSION The combination of starch source mesoporous carbon carrier and double-layer osmotic pump technology prevente the burst effect and significantly improve the oral absorption of FNB.     

����˹������֬��������������Ʊ�������������

??OBJECTIVE To prepare pyridostigmine bromide-phospholipids complex nanoemulsion (PPNE) and carry out in vitro and in vivo evaluation. METHODS The pyridostigmine bromide-phospholipids and PPNE were prepared by solvent evaporation method and pseudo-ternary phase diagram method, respectively. The morphology, particle size, Zeta potential, in vitro release and oral bioavailability of PPNE were evaluated. RESULTS The PPNE was approximately circular. The particle size and Zeta potential were 26.16 nm and -3.88 mV, respectively. The in vitro release behavior of PPNE was similar to pyridostigmine bromide. The relative oral bioavailability of PPNE was 208.1% to pyridostigmine bromide. CONCLUSION PPNE was successfully prepared with a simple and repeatable method, which may be a fundamental formulation for further research of pyridostigmine bromide.     

�Ǿ���-��������㸴�ϲ����Ʊ��װ����ʻ���΢���������ͷŵ��о�

??OBJECTIVE To prepare a novel methotrexate sustained-release microspheres system, and study its in vitro release properties. METHODS The CS-montmorillonite (CS-MMT) intercalative composites were prepared by using chitosan and montmorillonite. The novel drug sustained-release system was prepared with CS-MMT as the carrier material and methotrexate as the model drug. The microspheres were characterized by Fourier transform infrared spectrometer (FTIR), electric microscope, UV-spectrophotometer (UV), as well as Malvernlaser particle size analyzer. The influences of the amount of composite materials, dosage of emulsifiers, ratio of oil/water and dosage of crosslinking agent on the drug loading and entrapment rate of microspheres were investigated. And in vitro release experiment was used to study the drug release properties of the microspheres. RESULTS The shape and size of the microspheres were uniform. The drug loading, average particle size and Zeta potential were 31.6%, 557.4 nm and 20.8 mV respectively under the optimal conditions, ie, ratio of water/oil of 1??5, amount of glutaraldehyde(aqueous phase)of 6%, dosage of emulsifiers (oil phase) of 7%, CS-MMT/CS ratio of 1??4, and MTX/CS ratio of 1??3. Methotrexate sustained-release system was pH-sensitive and tended to show a larger release percentage in hydrochloric acid solution. CONCLUSION CS-MMT can be used as a slow-release excipient. CS-MMT microspheres are good controlled-release carrier for drugs, with pH sensitivity.     

巨噬细胞膜仿生白蛋白纳米体系的构建及其胶质瘤靶向递药性能评价

目的 构建包载WEE1激酶抑制剂adavosertib的巨噬细胞膜仿生白蛋白纳米粒(MM-BSA/Ada),体外评估其作为胶质瘤靶向递药体系的可行性。方法 制备MM-BSA/Ada并筛选最佳膜-核比和最佳药-载比,检测其载体安全性和对C6胶质瘤细胞抗增殖活性,考察其体外细胞摄取、跨血脑屏障转运和跨膜后摄取的能力。结果 MM-BSA/Ada具有良好的稳定性,CCK-8结果初步显示,未载药纳米粒在体外细胞实验中对脑血管内皮细胞呈低毒性;与未包膜纳米粒和游离药物相比,MM-BSA/Ada给药后的体外抗胶质瘤细胞增殖活性(P＜0.001)、胶质瘤细胞摄取量(P＜0.001)、体外血脑屏障透过量(P＜0.01)及跨膜后摄取量(P＜0.001)均显著提高。结论 MM-BSA/Ada有较好的胶质瘤靶向递药性能,有望为胶质瘤提供新的放射增敏策略。     

�ظ��ڼ��ؿ�ע��Ǿ���/��-��������������ˮ�������Ʊ��������о�

??OBJECTIVE To prepare lappaconitine(LA)-loaded chitosan/ sodium ??-glycerophosphate(CS/??-GP) thermosensitive hydrogels and investigate its phase transition mechanism of gel formation process and release properties in vitro. METHODS The injectable CS/??-GP thermosensitive hydrogels were prepared with biodegradable CS as carrier material and ??-GP as coagulation accelerator. The release behavior in vitro was studied by dynamic dialysis, and the phase transition mechanism of gel formation process was further investigated by rheological method. RESULTS The optimized process condition was as follows:the concentration of ??-GP and CS was 560 and 22 mg??mL^-1, respectively, CS was dissolved by 0.1 mol??L^-1 HOAc, and the valume ratio of CS to ??-GP was 8.75??1.25(V/V), the gelation time of CS/??-GP thermosensitive hydrogels with volume ratio of 8.75??1.25(V/V) at 37 ?? was 5 min 38 s. The in vitro release study showed that these injectable CS/??-GP thermosensitive hydrogels had sustained release effect for LA, and the release behavior could be well described by the Higuchi model and Korsmeyer-Peppas model. The mechanism of LA releasing from CS/??-GP thermosensitive hydrogels was attributed to drug dissolution and diffusion. Rheological studies showed that the CS/??-GP thermosensitive hydrogels belonged to thixotropic system and exhibited non-Newtonian and shear-thinning fluid behavior as well as ??solid-like?? gelatin behavior. CONCLUSION LA-Loaded CS/??-GP injectable thermosensitive hydrogels with good elasticity and gel strength properties are prepared successfully, and they show sustained release effect of LA in vitro.